These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 25050704

  • 1. The effects of CAMPATH-1H on cell viability do not correlate to the CD52 density on the cell surface.
    Lee F, Luevano M, Veys P, Yong K, Madrigal A, Shaw BE, Saudemont A.
    PLoS One; 2014; 9(7):e103254. PubMed ID: 25050704
    [Abstract] [Full Text] [Related]

  • 2. Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
    Williams RJ, Clarke E, Blair A, Evely R, Hale G, Waldmann H, Brookes S, Pamphilon DH.
    Cytotherapy; 2000; 2(1):5-14. PubMed ID: 12042050
    [Abstract] [Full Text] [Related]

  • 3. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation.
    Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW.
    Blood; 2003 Feb 15; 101(4):1422-9. PubMed ID: 12393688
    [Abstract] [Full Text] [Related]

  • 4. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis.
    Jordan MB, McClain KL, Yan X, Hicks J, Jaffe R.
    Pediatr Blood Cancer; 2005 Mar 15; 44(3):251-4. PubMed ID: 15390358
    [Abstract] [Full Text] [Related]

  • 5. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H.
    Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer MJ, Catovsky D.
    Leuk Res; 1998 Feb 15; 22(2):185-91. PubMed ID: 9593475
    [Abstract] [Full Text] [Related]

  • 6. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
    Zhang Z, Zhang M, Goldman CK, Ravetch JV, Waldmann TA.
    Cancer Res; 2003 Oct 01; 63(19):6453-7. PubMed ID: 14559836
    [Abstract] [Full Text] [Related]

  • 7. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis.
    Rao SP, Sancho J, Campos-Rivera J, Boutin PM, Severy PB, Weeden T, Shankara S, Roberts BL, Kaplan JM.
    PLoS One; 2012 Oct 01; 7(6):e39416. PubMed ID: 22761788
    [Abstract] [Full Text] [Related]

  • 8. The CD45 tyrosine phosphatase regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in human T cells.
    Hederer RA, Guntermann C, Miller N, Nagy P, Szollosi J, Damjanovich S, Hale G, Alexander DR.
    Int Immunol; 2000 Apr 01; 12(4):505-16. PubMed ID: 10744652
    [Abstract] [Full Text] [Related]

  • 9. Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52).
    Osterborg A, Werner A, Halapi E, Lundin J, Harmenberg U, Wigzell H, Mellstedt H.
    Eur J Haematol; 1997 Jan 01; 58(1):5-13. PubMed ID: 9020367
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of CAMPATH-1H in BMT patients.
    Rebello P, Cwynarski K, Varughese M, Eades A, Apperley JF, Hale G.
    Cytotherapy; 2001 Jan 01; 3(4):261-7. PubMed ID: 12171714
    [Abstract] [Full Text] [Related]

  • 11. Ex vivo-expanded cynomolgus macaque regulatory T cells are resistant to alemtuzumab-mediated cytotoxicity.
    Dons EM, Raimondi G, Zhang H, Zahorchak AF, Bhama JK, Lu L, Ezzelarab M, Ijzermans JN, Cooper DK, Thomson AW.
    Am J Transplant; 2013 Aug 01; 13(8):2169-78. PubMed ID: 23635093
    [Abstract] [Full Text] [Related]

  • 12. CD52 is a molecular target in advanced systemic mastocytosis.
    Hoermann G, Blatt K, Greiner G, Putz EM, Berger A, Herrmann H, Cerny-Reiterer S, Gleixner KV, Walz C, Hoetzenecker K, Müllauer L, Reiter A, Sotlar K, Sexl V, Valent P, Mayerhofer M.
    FASEB J; 2014 Aug 01; 28(8):3540-51. PubMed ID: 24760752
    [Abstract] [Full Text] [Related]

  • 13. Emergence of CD52-, glycosylphosphatidylinositol-anchor-deficient lymphocytes in rheumatoid arthritis patients following Campath-1H treatment.
    Brett SJ, Baxter G, Cooper H, Rowan W, Regan T, Tite J, Rapson N.
    Int Immunol; 1996 Mar 01; 8(3):325-34. PubMed ID: 8671618
    [Abstract] [Full Text] [Related]

  • 14. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.
    Jiang L, Yuan CM, Hubacheck J, Janik JE, Wilson W, Morris JC, Jasper GA, Stetler-Stevenson M.
    Br J Haematol; 2009 Apr 01; 145(2):173-9. PubMed ID: 19236377
    [Abstract] [Full Text] [Related]

  • 15. CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment.
    Hotta R, Ohira M, Matsuura T, Muraoka I, Tryphonopoulos P, Fan J, Tekin A, Selvaggi G, Levi D, Ruiz P, Ricordi C, Vianna R, Ohdan H, Waldmann H, Tzakis AG, Nishida S.
    PLoS One; 2016 Apr 01; 11(8):e0161618. PubMed ID: 27560943
    [Abstract] [Full Text] [Related]

  • 16. Antibody selection against CD52 produces a paroxysmal nocturnal haemoglobinuria phenotype in human lymphocytes by a novel mechanism.
    Taylor VC, Sims M, Brett S, Field MC.
    Biochem J; 1997 Mar 15; 322 ( Pt 3)(Pt 3):919-25. PubMed ID: 9148769
    [Abstract] [Full Text] [Related]

  • 17. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab.
    Buggins AG, Mufti GJ, Salisbury J, Codd J, Westwood N, Arno M, Fishlock K, Pagliuca A, Devereux S.
    Blood; 2002 Sep 01; 100(5):1715-20. PubMed ID: 12176892
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic potential of CAMPATH-1H in skeletal tumours.
    Fritsche-Guenther R, Gruetzkau A, Noske A, Melcher I, Schaser KD, Schlag PM, Kasper HU, Krenn V, Sers C.
    Histopathology; 2010 Dec 01; 57(6):851-61. PubMed ID: 21166699
    [Abstract] [Full Text] [Related]

  • 19. Alemtuzumab for the prevention and treatment of graft-versus-host disease.
    Kanda J, Lopez RD, Rizzieri DA.
    Int J Hematol; 2011 May 01; 93(5):586-593. PubMed ID: 21369856
    [Abstract] [Full Text] [Related]

  • 20. Anti-CD52 antibody-mediated immune ablation with autologous immune recovery for the treatment of refractory juvenile polymyositis.
    Reiff A, Shaham B, Weinberg KI, Crooks GM, Parkman R.
    J Clin Immunol; 2011 Aug 01; 31(4):615-22. PubMed ID: 21541793
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.